Thermosome

Thermosome is a clinical-stage drug development company that focuses on targeted tumor therapy and immune stimulation to improve cancer treatment. At its core is a new, proprietary tumor-targeting approach that can significantly increase local drug concentration and enhance tumor penetration, thereby improving clinical efficacy. Thermosome's method enables targeted tumor therapy independent of specific molecular targets and covers patient populations across all tumor subtypes. The first clinical indication for its lead candidate drug, THE001, is soft tissue sarcoma, with the aim of raising the current standard of care.